DOCSLIB.ORG

Wellcome Trust 1974-76

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Wellcome Trust 1974-76 The Wellcome Trust 1974-76 Eleventh Report 2 «j.:t -t^" of ^-^^e_J 22501470048 The Trustees© first meeting in the Board Room at 1 Park Square West, October 1974 L. to R.: Prof. H. Barcroft, Prof. R. H. S. Thompson, Dr. Edda Hanington (Deputy Secretary), Dr. P. O. Williams (Secretary), Lord Franks, Lord Armstrong, Sir John McMichael, Sir Michael Swann, Dr. C. E. Gordon Smith The Wellcome Trust 1974-76 Eleventh Report 1 Park Square West, London NWI 4LJ •V7——©7 CONTENTS I Introduction and Policy 7 II Grants Programme 13 A. SUPPORT OF MEDICAL RESEARCH IN GREAT BRITAIN 16 University Development 16 Departmental Support 16 Interdisciplinary Linkage 18 Research Leave 22 Subjects Selected for Development 24 Dermatology 24 Mental Health 27 Wellcome Senior Research Fellowships in Clinical Science 30 Clinical Sciences 33 Basic Sciences 55 B. SUPPORT OF MEDICAL RESEARCH OVERSEAS 83 Tropical Medicine 83 European Programme 99 Other Overseas Awards 112 C. VETERINARY AND COMPARATIVE MEDICINE 118 D. HISTORY OF MEDICINE 125 III The Trustees and their Staff 134 Wellcome Trust Advisory Panels 137 Appendix I Policy 1975-76 138 Index of Subjects 141 Index of Research Grantholders 142 The Wellcome Trust Board of Trustees: Chairman: The Rt. Hon. the Lord Franks, PC., G.C.M.G., K.C.B., C.B.E. Deputy Chairman: Professor Sir John McMichael, M.D., F.R.C.P., F.R.S. Trustees: Professor R. H. S. Thompson, C.B.E., D.M., D.SC., F.R.C.P., F.R.c.Path., F.R.S. Professor H. Barcroft, M.D., F.R.C.P., F.R.S. (Until December 1974). C. E. Gordon Smith, C.B., M.D., F.R.C.P., F.R.c.Path. Sir Michael Swann, F.R.S. The Rt. Hon. the Lord Armstrong of Sanderstead, G.C.B., M.V.O. Professor W. S. Peart, M.D., F.R.C.P., F.R.S. (From January 1975). Secretary: P. O. Williams, M.A., M.B., F.R.C.P. Deputy Secretary: Edda Hanington, M.D., M.R.C.P. The Wellcome Trust Staff of the Trust (as at 31st August 1976) Director; P. O. Williams, M.A., M.B., F.R.C.P. Medical Division: Edda Hanington, M.D., M.R.C.P., Assistant Director B. A. Bembridge, M.D., Assistant Director D. G. Metcalfe, Scientific Administrative Officer F. A. Griffin, Administrative Assistant Tropical Medical Division : B. E. C. Hopwood, M.R.C.S., D.P.H., D.I.H., Bar-at-Law Gillian Breen, LL.B., Administrative Assistant Finance Division: K. C. Stephenson, M.C., F.C.A., Finance Officer D. L. Freeman, Accountant Administrative Division: M. A. F. Barren, Administrative Officer D. G. Hooker, Office Manager Director©s Office: Pamela Bradburne, B.SC., Administrative Assistant Joan E. Masom, Director's Secretary The First 40 Years of The Wellcome Trust Sir Henry Wellcome died on 25th July 1936. The Wellcome Trust is therefore 40 years old. During this time it has allocated £34.5m for the support of medical research and medical history. Its growth is illustrated by the fact that during its first 20 years it distributed Elm, in the next ten years a further £8.5m and between 1966 and 1976 £25m. The Wellcome Trust is now the largest endowed charitable Trust supporting medical research in the United Kingdom and plays a significant role both in this country and the tropics. The present strength of the Wellcome Trust is the result of the expansion of the international pharmaceutical company, The Wellcome Founda tion Limited, which was founded by Sir Henry Wellcome and of which the Wellcome Trustees are the sole shareholders. I INTRODUCTION AND POLICY It is an essential requirement for every modern society that it should retain sufficient flexibility to be able to adopt new ideas and developments of importance. This necessitates the provision of opportunity, encouragement and continued appraisal of new people and new suggestions. Lack of such flexibility leads to a state of depression, so that new ideas are not put forward because it seems inevitable that they will not be financed. For many years we have watched the steady growth in expenditure on the Health Service, the Universities and the Research Councils although a closer look suggests that because of inflation much of this growth is more apparent than real. Nevertheless, until recently, within the budgets of these bodies there has always been the opportunity for new developments. During such a growth phase it did not, on the whole, cause concern that health care, higher educa tion and research had largely developed into government financed monopolies. During the past year the situation has changed. The Uni versities, the Health Service and the Research Councils have ceased to grow and in most cases, because of inflation, there has been an effective reduction in their resources. The result has been that the Universities have had to cut back on their staffing and running costs so as to keep within their budgets. The number of new posts becoming available in academic medicine is therefore small and such as occur are inevitably related to the requirements of patient care and teaching. In the past, a deficiency of this kind might have been cushioned by a transfer of funds from the Health Service or the Medical Research Council. Such alternatives are no longer readily available. The overall effect on those in post is mainly of significance because they have to spend more of their time, since fewer colleagues are available, on clinical work, teaching and administration and hence less on the pursuit of innovation and research. The impending shortage of Government funds for running expenses and technical assistance for research work of high quality will make it even more difficult for university staff to undertake research. The virtual cessation of the provision of equipment grants will, in due course, create real difficulties especially as costs rise. This is the general situation which we can anticipate will continue for several years. It has perhaps not been surprising that the growth which we have seen for many years should cease and so we should, in any case, have had to learn to deal with the situation that now exists. Unfortunately the growth period has not been sufficiently long to reach the position where retirement will create enough vacancies for a reasonable level of recruit ment. The pressure on the Medical Research Council to economise and to give permanent appointments to its staff has also resulted in a reduced number of posts becoming available. Opportunities are very limited for young men and women who may be considering making their future in academic medicine. Not only are suitable posts in short supply, but so also are the financial rewards which are relatively much less good for university staff than those in the Health Service. Despite these deterrents to a career in academic medicine, there are still young men and women who are so enthusiastic about the importance and interest of medical research that they are prepared to accept the risks in their career prospects and make financial sacrifices so as to pursue their ideas. The attractions of posts overseas once more become highly significant. The position is inevitably more difficult for those without a medical quali fication, as the alternative of a clinical appointment in the last resort is not available. We have therefore reached a no-growth situation when medicine and higher education are largely a monopoly of government. Charitable funds provide an alternative but the quantity clearly can never be sufficient to have a major impact on the general situation. However, focused on particular prob lems, private funds have a special opportunity to assist in preserving the high quality of British academic medicine just when it is needed. The Wellcome Trust has carefully considered its policy in the light of present events. It has found that the suggestion made in its last report that Trust funds should be used to help Universities to develop their own innovative plans did not receive the response that might have been anticipated. The reason, apparently, was the inability of the Universities to plan new developments in such a shifting situation. It was as much as they could do to keep within their budgets. During the past two years, the Trustees have been very conscious of these and other factors that are having an adverse effect on medical research. In order to keep them selves informed, they have held numerous informal con sultations with individuals and groups in the Universities and with organisations such as the Committee of Vice- Chancellors, the University Grants Committee and the Medical Research Council. They have also kept in touch with the world of Foundations and Charities through the Standing Conference of Medical Research Charities. In addition, they held two meetings in which every university medical school participated to obtain views on the present problems and likely requirements for the future. Dr. Williams personally visited the Universities of Oxford, Cambridge, Birmingham, Bristol and Dundee and the Medical Schools of St. Mary's, Charing Cross, King's, St. Thomas's, the Royal Postgraduate Medical School and the London School of Hygiene and Tropical Medicine for dis cussions on Research Policy at meetings of Departmental Heads and others. He also saw the Deans or other repre sentatives of most of the other medical schools. The results of all these contacts were brought together at two major policy meetings of the Trustees held in July 1975 and May 1976. At these meetings, the Trustees examined their policy on a variety of topics and decided how best to allocate their resources for the future.
Load more

Recommended publications
  • René Dubos, Tuberculosis, and the “Ecological Facets of Virulence”
    HPLS (2017) 39:15 DOI 10.1007/s40656-017-0142-5 ORIGINAL PAPER René Dubos, tuberculosis, and the “ecological facets of virulence” Mark Honigsbaum1 Received: 15 January 2017 / Accepted: 23 June 2017 / Published online: 4 July 2017 © The Author(s) 2017. This article is an open access publication Abstract Reflecting on his scientific career toward the end of his life, the French- educated medical researcher Rene´ Dubos presented his flowering as an ecological thinker as a story of linear progression—the inevitable product of the intellectual seeds planted in his youth. But how much store should we set by Dubos’s account of his ecological journey? Resisting retrospective biographical readings, this paper seeks to relate the development of Dubos’s ecological ideas to his experimental practices and his career as a laboratory researcher. In particular, I focus on Dubos’s studies of tuberculosis at the Rockefeller Institute in the period 1944–1956—studies which began with an inquiry into the tubercle bacillus and the physiochemical determinants of virulence, but which soon encompassed a wider investigation of the influence of environmental forces and host–parasite interactions on susceptibility and resistance to infection in animal models. At the same time, through a close reading of Dubos’s scientific papers and correspondence, I show how he both drew on and distinguished his ecological ideas from those of other medical researchers such as Theobald Smith, Frank Macfarlane Burnet, and Frank Fenner. However, whereas Burnet and Fenner tended to view ecological interactions at the level of populations, Dubos focused on the interface of hosts and parasites in the physio- logical environments of individuals.
    [Show full text]
  • The Miracle of the Mould Howard Florey and Colleagues Overcame Great Obstacles to Isolate Penicillin
    books and arts The miracle of the mould Howard Florey and colleagues overcame great obstacles to isolate penicillin. The Mould in Dr Florey’s Coat: The Remarkable True Story of the Penicillin Miracle by Eric Lax Little, Brown: 2004. 288 pp. £16.99 William Shaw HAAS/BETTMANN/CORBIS D. Well-researched and readable accounts of medical science and disease are always wel- come. The first thing to note about this new work by Eric Lax, whose earlier efforts have been a well-regarded biography of Woody Allen and an engaging account of cancer chemotherapy, is that its title prom- ises a great deal — and does so rather late in the day. There is little doubt that, after more than half a century of personal reflections and scholarship, the story of the emergence of penicillin as a life-saving medicine remains remarkable — not least for the obstacles overcome and for the personalities of the trio of Nobel laureates involved: Alexander Fleming, Howard Florey and Ernst Chain. But promise of a true story begs the question of what has been on offer since 1945. And was there a miracle? Well, nearly, at least in the sense that the small team assembled by Florey at the Sir William Dunn School of Norman Heatley (below left) oversaw the mass production of penicillin in 1940s America. Pathology in Oxford, UK, in the dark and difficult early honorary doctorate of medi- from farther afield, such as the Yale papers years of the Second World cine, the first non-medical of John Fulton, Florey’s close friend and War, hardly seemed like a person to be so honoured.
    [Show full text]
  • Bulletin of Tibetology
    Bulletin of Tibetology NEW SERIES 1990 No. 1-3 9 November 1990 SIKKIM RESEARCH INSTITUTE OF TIBETOLOOY GANGTOK, INDIA - The Bulletin ofTibetology seeks to serve the specialist as well as the general reader with an interest in this field of study. The motif portraying the Stupa on the mountains suggests the dimensions of the field - EDnORS JAMPAL K. RECHUNG KUNGA YONTEN HOCHaISANG BHAJAGOVINDA GHOSH Bulletin of Tibetology NEW SERIES 1990 No. 1-3 9 November 1990 SIKKIM RESEARCH INSTITUTE OF TIBETOLOGY GANGTOK, INDIA LCHAGS-RTA : LHABAB DUECHBN 9 November 1990 Price per copy Rs. 25 1- 7/91 PUBLISHED BY TIlE DIRECTOR SIKKIM RESEARCH INSTITUTE OF TIBETOLOOY GANGTOK - 737 101. SIKKIM PRINTED AT HIMALINDIA PHOTO OFFSET NAM NAM ROAD,GANGTOK CONTENTS Page 1 SAKY AMUNI'S FINAL NIRVANA - David L. Snellgrove 5 2 BUDDHARUPA -- OBSERVATION ON THE EVOLUTION OF BUDDHA IMAGE - Ninnal C. Sinha 18 3 HINAY ANA AND MAHAYANA - A BROAD OUTLINE - Anukul Chandra Banerjee 23 4 VAIDURYA - Marianne Winder 27 5 THE CONFLICT BETWEEN THE BUDDlllST AND THE NAlY AYIKA PHILOSOPHERS - A BRIEF SURVEY - Dr. Sanjit Kumar Sadhukhan 39 6 THE BUDDlllST PAINTINGS AND ICONOGRAPHY ACCORDING TO TIBETAN SOURCES - J.K. Rechung 55 7 NOTES & TOPICS - H.R. Bhattacharyya 65 CONTRmUTORS IN THIS ISSUE: DAVID L. SNELLGROVE, Fellow of the British Academy. formerly Professor of Tibetan. the School of Oriental and African Studies. University of London. Had travelled extensively in India and Nepal. made critical studies of the Hevajra-Tantra on the basis of extant Sanskrit mss and Tibetan version. Made Critical study on early Religion of Tibet-Bon.
    [Show full text]
  • DAVID NACHMANSOHN March 17, 1899-November 2, 1983
    NATIONAL ACADEMY OF SCIENCES D A V I D N ACHMANSOHN 1899—1983 A Biographical Memoir by SEVERO OCHOA Any opinions expressed in this memoir are those of the author(s) and do not necessarily reflect the views of the National Academy of Sciences. Biographical Memoir COPYRIGHT 1989 NATIONAL ACADEMY OF SCIENCES WASHINGTON D.C. DAVID NACHMANSOHN March 17, 1899-November 2, 1983 BY SEVERO OCHOA AVID NACHMANSOHN'S scientific life path was strongly D influenced by his early studies on the biochemistry of muscle in Otto Meyerhof's laboratory. This experience led to an interest in the biochemistry of nerve activity, a field of study to which he would devote most of his scientific life. In so doing, he contributed—perhaps more than any other in- vestigator—to our understanding of the molecular basis of bioelectricity. David Nachmansohn was born in Jekaterinoslav, Russia (now Dnjetropetrowsk, USSR). His parents came from middle-class families among whom were many lawyers, phy- sicians, and other professionals. Before David and his two sisters reached school age, the family moved to Berlin where they had many relatives. Thus, David's background and edu- cation were essentially, if not exclusively, German. His college education was strongly humanistic, with Latin, Greek, liter- ature, and history as mainstays, some mathematics, and the rudiments of physics. Through his readings, perhaps pri- marily through his reading of the second part of Goethe's Faust when he was only seventeen years of age, he became interested in philosophy—so much so that he continued to attend courses and seminars in philosophy even while a med- ical student at Heidelberg in 1920.
    [Show full text]
  • Speaker's Manuscript
    Nobel Prize Lessons 2018 Speaker’s manuscript – the 2018 Medicine Prize The Nobel Prize in Physiology or Medicine • The Nobel Prize in Physiology or Medicine is one of the five prizes founded by Alfred Nobel and awarded on December 10 every year. Before Alfred Nobel died on December 10, 1896, he wrote in his will that the largest part of his fortune should be placed in a fund. The yearly interest on this fund would pay for a prize given to “those who, during the preceding year, shall have conferred the greatest benefit to humankind.” Who is rewarded with the Medicine Prize? • The Nobel Prize in Physiology or Medicine is thus awarded to people who have either made a discovery about how organisms work or have helped find a cure for a disease. • This is May-Britt Moser, 2014 Nobel Laureate in Medicine. In 2005 she and Edvard Moser discovered a type of cell in the brain that is important for determining one's position. They also found that those cells cooperate with different nerve cells in the brain that help us to navigate. You can say that the Laureates discovered and explained a kind of GPS system in the brain. • Other Medicine Laureates include: • Francis Crick, James Watson and Maurice Wilkins, who received the 1962 Prize for their discoveries and descriptions about the structure of DNA molecules. • Alexander Fleming, Ernst Chain and Howard Florey, who received the 1945 Prize for the discovery of penicillin and its curative effects on bacterial diseases. Medicine Prize 2018 • The 2018 Nobel Prize is about a new way of treating cancer.
    [Show full text]
  • Physiological Society Template
    An interview with Ron Whittam Conducted by David Miller and Richard Naftalin on 12 August 2014 Published December 2019 This is the transcript of an interview of the Oral Histories Project for The Society's History & Archives Committee. The original digital sound recording is lodged with The Society and will be placed in its archive at The Wellcome Library. An interview with Ron Whittam Ron Whittam photographed by David Miller This interview with Ron Whittam (RW) was conducted by David Miller (DM) and Richard Naftalin (RN) on 12 August 2014 DM: Let’s make sure we’re starting. Fine. So okay this is David Miller, it’s the 12th August 2014 and we’re are in Leicester at the home of Professor Ron Whittam and we’re here to record for the oral history project of the Physiological Society. So, also here is Richard Naftalin whose voice you’ll hear and Ron Whittam himself, of course. So we’re going to run through elements of Ron’s life and background as he wishes to cover in the usual way. So that’s enough from me. Perhaps Richard if you could just say a few words so that it’s recognised whose voice is whose. RN: Okay, well I’m Richard Naftalin. I’m currently Emeritus Professor at King’s College London but I was, had the privilege of being, in Leicester University and I was appointed lecturer to Ron Whittam’s department of General Physiology in 1968. I came to Leicester as newlywed and as a virgin physiologist to Ron’s department so that was very exciting –at least for me.
    [Show full text]
  • Alexander Fleming, Ernst Chain Och Howard Florey NOBELPRISET I FYSIOLOGI ELLER MEDICIN 1945
    Alexander Fleming, Ernst Chain och Howard Florey NOBELPRISET I FYSIOLOGI ELLER MEDICIN 1945 ”för upptäckten av penicillinet och dess botande verkan vid olika infektionssjukdomar” Nobelstiftelsen© Nobelstiftelsen© Nobelstiftelsen© Fleming tillhörde inte de mest fanatiska forskarna. Han drack ”afternoon tea”, spelade biljard, schack, kort, tog en Sir Alexander Fleming Sir Ernst Boris Chain Sir Howard Walter Florey drink för att sedan gå hem * 6 augusti 1881 i Lochfield, * 19 juni 1906 i Berlin, * 24 september 1898 i Ade- Skottland Tyskland laide, Australien till familjen och äta middag † 11 mars 1955 i London, † 12 augusti 1979 i Mulrany, † 21 februari 1968 i Oxford, England Ireland England klockan åtta på kvällarna. Alexander Fleming upptäcker 1928 att ett och blodförgiftning till döden. Idag kan vi med mögel har växt i en av hans bakterieodlingar. penicillin eller motsvarande antibiotika bota Runt möglet har bakterierna dött. I de andra dem. Men för stor användning av antibiotika proverna, där det inte finns mögel har bak- har också lett till att bakterier blivit resistenta. terierna växt normalt. Fleming inser snabbt Detta innebär att det börjar bli allt vanligare att det här är en fantastisk upptäckt. Kan man med bakteriesjukdomar som inte går att bota använda den här mögelsvampen som medi- med de antibiotika som finns tillgängliga idag. cin? Han börjar odla den speciella svampen Det finns därför ett stort behov av att hitta nya i större skala, för att få möjlighet att också former av antibiotika. Redan 1945 i sin Nobel- testa den på bakterier som angripit djur och föreläsning varnade Fleming för att bakterier det fungerar. lätt kan utveckla motståndskraft mot penicil- linet om det används fel.
    [Show full text]
  • The Worshipful Society of Apothecaries of London Galen Medal Winners
    The Worshipful Society of Apothecaries of London Galen Medal Winners 1926 Prof WE DIXON, BSc, MA, MD, DPH, FRS Pharmacology 1927 Sir Gowland HOPKINS, MA, LLD, DSc, FRCP, FRIC, FRS Discovery of vitamins 1928 Prof JJ ABEL, MD, ScD, LLD Isolation of Adrenaline 1930 Prof E FOURNEAU, Directeur de 1'Institute Pasteur Pharmacology of amino-alcohols 1932 Sir Henry DALE, OM, GBE, MA, MD, FRCP, FRS Neurophysiology 1934 Prof Sir Frederick BANTING, MC, Hon FRCS, DSc, LLD Discovery of Insulin 1946 Sir Alexander FLEMING, FRCP, FRCS, FRS Penicillin Lord FLOREY, MA, MD, FRCP, FRS 1947 F CURD, BSc, PhD D DAVEY, MSc, PhD Discovery of Paludrine F ROSE, BSc, PhD 1948 Sir Lionel WHITBY, CVO, MC, MD, FRCP Sulphonamides 1949 Prof J TREFOUEL, Directeur de 1'Institute Pasteur Sulphonamides 1951 Prof Sir Charles DODDS, Bt, MVO, MD, FRCP, FRS Biochemistry 1953 Sir Charles HARINGTON, MA, PhD, FRS Synthesised Thyroxin 1954 EL SMITH, DSc, FRIC Vitamin B12 1955 Lord BROCK, MS, FRCS Cardiac surgery 1957 Prof Sir Ernst CHAIN, MA, DPhil, FRS Production of Penicillin 1958 Sir Macfarlane BURNET, OM, MD, FRCP, FRS Vaccines for virus infections 1959 Prof Sir Bradford HILL, CBE, PhD, DSc, FRS Medical statistics 1960 Sir Tudor THOMAS, DSc, MD, MS, FRCS Corneo-plastic surgery 1961 Prof R PATERSON, CBE, MC, MD, FRCS, FFR Radiotherapy 1962 Prof W PENFIELD, OM, CMG, MD, DSc, FRS Neurosurgery & Neurophysiology 1963 Prof Sir Alexander HADDOW, MD, DSc, PhD, FRS Experimental pathology & cancer research 1964 FP DOYLE, MSc, FRIC Chemical & biological GN ROLINSON, BSc, PhD development
    [Show full text]
  • Microbiologytoday
    microbiologytoday microbiology vol36|feb09 quarterly magazine of the society today for general microbiology vol 36 | feb 09 the legacy of fleming ‘that’s funny!’: the discovery of penicillin what manner of man was fleming? the future of antibiotic discovery look who’s talking when good bugs fight bad contents vol36(1) regular features 2 News 38 Schoolzone 46 Hot off the Press 10 Microshorts 42 Gradline 49 Going Public 36 Conferences 45 Addresses 60 Reviews other items 33 The Defra-commissioned independent review of bovine tuberculosis research 54 Education Development Fund report 58 Obituary – Professor Sir James Baddiley FRS 59 Obituary – Emeritus Professor Naomi Datta FRS articles 12 ‘That’s funny!’: the 24 Look who’s talking! discovery and development Julian Davies of penicillin Antibiotics aren’t just for fighting infections; they are part of the bacterial signalling network. Kevin Brown The chance discovery of penicillin 80 years ago made Alexander Fleming a famous scientist. 28 When good bugs fight bad Roy Sleator 16 What manner of man was There are alternative methods available Alexander Fleming? for combating infectious diseases – not just antimicrobial chemotherapy. Philip Mortimer Alexander Fleming, the Society’s first President, did so much more than discover penicillin. 32 A precious memory Norberto Palleroni One of the few people left who met Fleming recounts his 20 Antibiotics and experience. Streptomyces: the future of antibiotic discovery 64 Comment: Debating creationism Flavia Marinelli Many options for drug discovery
    [Show full text]
  • Leading Research for Better Health
    < Contents > Contents Please click on the > to go directly to the page. > Introducing the MRC >AchievementsIntroducing thetimeline MRC Achievements>1913 to 1940s timeline >1950s to 1980s >1913 to 1940s >1990s to 2006 >1950s to 1980s >1990s to 2006 > Leading research for better health >NobelLeading Prize resear timelinech for better health Nobel>1929 Prizeto 1952 timeline >1953 to 1962 >1929 to 1952 >1972 to 1984 >1953 to 1962 >1997 to 2003 >1972 to 1984 1997 to 2003 >MRC research over the decades MRC> From resear discochvery over to healthcare:the decades translational research > EvidenceFrom discovery for best to pr healthcareactice: clinical — translational trials research > EvidencePublic health for bestresearch practice: clinical trials > PubDNAlic revhealtholution research > ReducingDNA rev olutionsmoking: preventing deaths > ReducingTherapeutic smoking: antibodiespreventing deaths > TherapeuticReducing deaths antibodies from infections in Africa > ReducingPreventing deaths heart fromdisease infections in Africa > PrevMedicalenting imaging: hearttransformingdisease diagnosis > MedicalCutting childimaging: leukaemia transforming deaths diagnosis > Cutting child leukaemia deaths < Click on any link to go< directly Contentsto a page >> < Contents > < Contents > < Contents > < Contents > Leading research for better health The most important part of the MRC’s mission trials, such as those on the use of statins to lower is to encourage and support high-quality research cholesterol and on vaccines in Africa.The MRC with the aim of improving human health.The MRC is the UK’s largest public funder of clinical trials is committed to supporting research across the and it supports some of the most productive entire spectrum of the biomedical and clinical and ambitious epidemiological studies in the world, sciences. We are proud of our international including the UK Biobank.
    [Show full text]
  • Antimcrobial Stewardship 11-11
    11/8/11 Antimicrobial Stewardship Protecting a Valuable Resource November 8, 2011 Edward Lifshitz, MD Medical Director Communicable Disease Service NJDHSS [email protected] (609) 826-5964 Edward Lifshitz, MD [email protected] “One can think of the middle of the twentieth century as the end of one of the most important social revolutions in history, the virtual elimination of infectious diseases as a significant factor in social life” 1962 Sir Frank MacFarlane Burnet Director of the Walter and Eliza Hall Institute of Medical Research 1960 Nobel Prize co-winner in Physiology or Medicine Edward Lifshitz, MD [email protected] “Unless we act to protect these medical miracles, we could be heading for a post-antibiotic age” 2001 Gro Harlem Brundtland WHO Director-General Edward Lifshitz, MD [email protected] 1 11/8/11 Antimicrobial Stewardship “Antimicrobial stewardship programs in hospitals seek to optimize antimicrobial prescribing in order to improve individual patient care as well as reduce hospital costs and slow the spread of antimicrobial resistance.” Clinical Microbiology Reviews, October 2005, p. 638-656, Vol. 18, No. 4 Edward Lifshitz, MD [email protected] Microbes vs Humans Microbes Microbes Humans by factor # on Earth 5 x 1031 7 x 109 ~ 1022 # cells in a Human 5 x 1013 5 x 1012 ~ 5 - 10 Mass - kg 5 x 1019 3 x 1011 ~ 108 Generation time 30 min 30 years ~ 5 x 105 Time on earth, years 3.5 x 109 4 x 106 ~ 103 Data: Schaechter M, et al, Microbiology in the 21st century:
    [Show full text]
  • 1901-2009 NOBEL PRIZE:1901-2009 O Prêmio Nobel De Medicina Desse Ano Foi Entregue a Elizabeth Blackbur
    EDITORIAL PRÊMIO NOBEL: 1901-2009 NOBEL PRIZE:1901-2009 Rosa Lúcia Vieira Maidana, Francisco Veríssimo Veronese, Sandra Pinho Silveiro O prêmio Nobel de Medicina desse ano foi entregue a Elizabeth Blackburn, Jack Szostak e Carol Greider (Figura 1) por terem elucidado a estrutura e o processo de manutenção dos telômeros, como descrevem didaticamente Jardim et al. nesse volume da revista (1). Elizabeth Blackburn (University of California, San Francisco, EUA), Jack Szostak (Harvard Medical School, Boston, EUA) e Carol Greider (Johns Hopkins University, Baltimore, EUA) descobriram que os telômeros são sequências de DNA situados nas extremidades dos cromossomos e possuem uma estrutura que protege os cromossomos de danos como a erosão. Também de- monstraram que uma enzima específica, a telomerase (descoberta em 1984 por Elizabeth Blackburn e sua então assistente Carol Greider), está envolvida no processo de reparação dos cromossomos após a mitose celular. Como descrevem Calado e Young em revisão publicada em dezembro de 2009 no New England Journal of Medicine (2), os telômeros e a telomerase são protetores contra danos ao genoma que podem surgir de uma replicação assimétrica do DNA. Sem os telômeros, o material genético poderia ser perdido toda vez que ocorre uma divisão celular. As implicações clínicas destes processos são importantes, uma vez que alte- rações nos telômeros estão causalmente relacionadas a patologias em que ocorre mutações genéticas, como a anemia aplásica. Telômeros curtos estão associados a risco aumentado de doença cardiovascular, e mutações no gene da telomerase a condições como fibrose pulmonar e hepática e susceptibilidade a alguns tipos de câncer (ex., coloretal, esôfago, leucemia mielóide).
    [Show full text]